Contemporary Management of HIV: Modifying ART in Virologically Suppressed Patients

Download this expert-authored slideset to review guidelines and key data on assessing virologic failure, current management options for patients with multiclass drug resistance experiencing treatment failure, and considerations for switching ART in patients with underlying resistance.
Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Paul E. Sax, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 636 KB
Released: March 2, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Vlog from Clinical Care Options (CCO) and Dr. Jehan Budak demonstrating HIV-ASSIST to guide ART selection in a HTE patient with HIV. Review of NRTI, NNRTI, PI, INSTI mutations, and more.

Jehan Budak, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Physician Assistants: maximum of 0.25 hour of AAPA Category ICME credit ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: July 27, 2021 Expired: July 26, 2022

Interim results from the Phase II CALIBRATE study of lenacapavir in treatment-naive PLWH, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

Large, retrospective analysis supports the effectiveness and safety of dolutegravir-based regimens among children and adolescents, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

IAS 2021 report from Clinical Care Options (CCO): CUSTOMIZE study shows that HCPs think monthly injectable CAB + RTV LA is feasible and acceptable despite COVID-19 disruptions

Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue